Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
The aim of the study is to test \[90\]Y-ibritumomab tiuxetan, a radioactive antibody, in patients with stage III or IV follicular lymphoma whose disease is in partial or complete remission after first line chemotherapy. The radioactive antibody will be compared with no further treatment to see which is better in the long term after standard lymphoma treatment.
Lymphoma, Non-Hodgkin
BIOLOGICAL: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|OTHER: no treatment
Progression free survival, End of study
Clinical and molecular response rates, End of study|Overall survival, End of study|Quality of Life, End of study|Adverse events / Toxicity Grading, Continous|Clinical laboratory results, 3 monthly|Vital signs / physical examination, 3 monthly|ECG, End of study|Co-medication, Continous
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.